Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+tumors when combined with an E6/E7 peptide vaccine

Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors

(2015) Y Sun et al.   GENE THERAPY

SA-4-1BBL and Monophosphoryl Lipid A Constitute an Efficacious Combination Adjuvant for Cancer Vaccines

(2014) A. K. Srivastava et al.   CANCER RESEARCH

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

(2014) Xiaozhou Fan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy

(2014) Chang Song et al.   OncoImmunology

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

(2013) Amy E Moran et al.   CURRENT OPINION IN IMMUNOLOGY

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin

(2013) Michael A. Curran et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Abstract 5445: Universal bioluminescent HTS-formatted assay for quantitation of ADP production in kinase and ATPase reactions

(2012) Said A. Goueli et al.   CANCER RESEARCH

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

(2012) C. Badoual et al.   CANCER RESEARCH

Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung

(2011) Amy N. Courtney et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

(2011) Michael A. Curran et al.   PLoS One

New Approaches to Immunotherapy for HPV Associated Cancers

(2011) Anne-Sophie Bergot et al.   Cancers

Gene Signature in Melanoma Associated With Clinical Activity

(2010) Thomas F. Gajewski et al.   CANCER JOURNAL

A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers

(2010) Loane Decrausaz et al.   INTERNATIONAL JOURNAL OF CANCER

Beyond Cervical Cancer: Burden of Other HPV-Related Cancers Among Men and Women

(2010) Anil K. Chaturvedi   JOURNAL OF ADOLESCENT HEALTH

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells

(2010) Daejin Kim et al.   VACCINE

IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway

(2009) Lin Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

E6 and E7 Gene Silencing and Transformed Phenotype of Human Papillomavirus 16-Positive Oropharyngeal Cancer Cells

(2009) T. Rampias et al.   JNCI-Journal of the National Cancer Institute

Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens

(2009) Amy N. Courtney et al.   VACCINE